Tango Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview

Tango Therapeutics

03/05/2024 17:17

* Tango Therapeutics Inc  TNGX.OQ   TNGX.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 7
(estimated) for the period ending March 31 2024
    * The Boston Massachusetts-based  company is expected to
report a
15.7% increase in revenue to $6.669 million from $5.77 million a
year ago, according to the mean estimate from 9 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Tango Therapeutics Inc
is for
a loss of 31 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Tango
Therapeutics Inc is $18.00​, above​ its last closing price
of $7.59. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.30       -0.28      -0.32     Missed  -15.2
 Sep. 30 0001  -0.34       -0.34      -0.23     Beat    33.3
 Jun. 30 2023  -0.31       -0.34      -0.23     Beat    31.5​
 Mar. 31 2023  -0.35       -0.35      -0.32     Beat    8.9
 ​​Dec.                    -0.35      -0.33     Beat    7
 31 2022                                                
 Sep. 30 2022  -0.32       -0.32      -0.33     Missed  -2.1​
 Jun. 30 2022  -0.32       -0.32      -0.28     Beat    13.6
 Mar. 31 2022  -0.28       -0.28      -0.29     Missed  -4.3
 This summary was machine generated May 3 at 16:16 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)